Collegium Pharmaceutical (NASDAQ:COLL) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a strong sell rating in a research note published on Tuesday,Zacks reports.

Other equities analysts have also issued reports about the stock. Oppenheimer began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $50.00 price objective on the stock. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, August 19th. Piper Sandler reaffirmed a “neutral” rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Finally, Leerink Partners began coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $48.71.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $22.11 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a 52-week low of $21.43 and a 52-week high of $50.79. The business’s 50-day moving average price is $25.40 and its 200 day moving average price is $31.28. The firm has a market cap of $719.81 million, a P/E ratio of 17.83, a P/E/G ratio of 0.71 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the firm earned $1.68 EPS. On average, equities research analysts expect that Collegium Pharmaceutical will post 6.21 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its stake in shares of Collegium Pharmaceutical by 23.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 16,406 shares of the specialty pharmaceutical company’s stock worth $358,000 after purchasing an additional 3,082 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $536,000. Squarepoint Ops LLC increased its holdings in shares of Collegium Pharmaceutical by 124.8% in the 2nd quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after purchasing an additional 26,589 shares in the last quarter. Corient Private Wealth LP lifted its stake in shares of Collegium Pharmaceutical by 60.5% in the second quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock valued at $2,603,000 after purchasing an additional 27,097 shares during the period. Finally, Amundi lifted its stake in shares of Collegium Pharmaceutical by 188.0% in the second quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock valued at $850,000 after purchasing an additional 15,336 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.

Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.